Ticker LaunchLaw firm
WilmerHale
WilmerHale is named in the Legal Matters section of 31 US IPO and 2 SPAC IPO prospectuses tracked by Ticker Launch since 2019, as company counsel on 17 and underwriters' counsel on 16.
US IPOs31
SPAC IPOs2
Deals by year: 2026: 1 · 2022: 3 · 2021: 12 · 2020: 11 · 2019: 6
Deals
| Company | Type | Date | Size | Role |
|---|---|---|---|---|
| Hemab Therapeutics Holdings, Inc. | IPO | May 1, 2026 | $301.5M | Company counsel |
| Arcellx, Inc. | IPO | Feb 7, 2022 | $123.8M | Underwriters' counsel |
| Amylyx Pharmaceuticals, Inc. | IPO | Jan 10, 2022 | $190M | Underwriters' counsel |
| CinCor Pharma, Inc. | IPO | Jan 7, 2022 | $193.6M | Underwriters' counsel |
| Jackson Acquisition Co | SPAC IPO | Dec 10, 2021 | $200M | Company counsel |
| Crescera Capital Acquisition Corp. | SPAC IPO | Nov 19, 2021 | $175M | Underwriters' counsel |
| Xilio Therapeutics, Inc. | IPO | Oct 22, 2021 | $117.6M | Company counsel |
| Theseus Pharmaceuticals, Inc. | IPO | Oct 7, 2021 | $160M | Underwriters' counsel |
| Cue Health Inc. | IPO | Sep 27, 2021 | — | Company counsel |
| Icosavax, Inc. | IPO | Jul 30, 2021 | $182M | Underwriters' counsel |
| Rallybio Corp | IPO | Jul 30, 2021 | $80.6M | Underwriters' counsel |
| Candel Therapeutics, Inc. | IPO | Jul 28, 2021 | $72M | Underwriters' counsel |
| Verve Therapeutics, Inc. | IPO | Jun 17, 2021 | $266.7M | Company counsel |
| Werewolf Therapeutics, Inc. | IPO | Apr 30, 2021 | $120M | Company counsel |
| ImageneBio, Inc. | IPO | Mar 26, 2021 | $125M | Underwriters' counsel |
| Decibel Therapeutics, Inc. | IPO | Feb 12, 2021 | $127.1M | Company counsel |
| Oncorus, Inc. | IPO | Oct 2, 2020 | $87M | Underwriters' counsel |
| CalciMedica, Inc. | IPO | Sep 25, 2020 | $90M | Underwriters' counsel |
| Dyne Therapeutics, Inc. | IPO | Sep 17, 2020 | $232.8M | Company counsel |
| Kymera Therapeutics, Inc. | IPO | Aug 21, 2020 | $173.7M | Underwriters' counsel |
| Inozyme Pharma, Inc. | IPO | Jul 24, 2020 | $112M | Company counsel |
| Pandion Therapeutics, Inc. | IPO | Jul 17, 2020 | $135M | Company counsel |
| Akouos, Inc. | IPO | Jun 26, 2020 | $212.5M | Company counsel |
| Forma Therapeutics Holdings, Inc. | IPO | Jun 22, 2020 | $277.6M | Underwriters' counsel |
| Generation Bio Co. | IPO | Jun 12, 2020 | $200M | Company counsel |
| Enliven Therapeutics, Inc. | IPO | Mar 12, 2020 | $75.2M | Company counsel |
| Schrodinger, Inc. | IPO | Feb 6, 2020 | $202M | Company counsel |
| Dynatrace, Inc. | IPO | Aug 1, 2019 | $569.8M | Underwriters' counsel |
| Fulcrum Therapeutics, Inc. | IPO | Jul 18, 2019 | $72M | Company counsel |
| Milestone Pharmaceuticals Inc. | IPO | May 9, 2019 | $82.5M | Underwriters' counsel |
| Trevi Therapeutics, Inc. | IPO | May 8, 2019 | $55M | Company counsel |
| Stealth BioTherapeutics Corp | IPO | Feb 15, 2019 | $78M | Company counsel |
| TCR2 Therapeutics Inc. | IPO | Feb 15, 2019 | $75M | Underwriters' counsel |
See where WilmerHale ranks: US IPOs · SPAC IPOs
Track WilmerHale's next deals
Subscribers get each new filing and pricing the morning after, with alerts and Excel export.